Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 63

1.

Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis.

Tuominen HJ, Tiihonen J, Wahlbeck K.

Schizophr Res. 2005 Jan 1;72(2-3):225-34. Review.

PMID:
15560967
[PubMed - indexed for MEDLINE]
2.

Glutamatergic drugs for schizophrenia.

Tuominen HJ, Tiihonen J, Wahlbeck K.

Cochrane Database Syst Rev. 2006 Apr 19;(2):CD003730. Review.

PMID:
16625590
[PubMed - indexed for MEDLINE]
3.

Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.

Singh SP, Singh V.

CNS Drugs. 2011 Oct 1;25(10):859-85. doi: 10.2165/11586650-000000000-00000.

PMID:
21936588
[PubMed - indexed for MEDLINE]
4.

The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.

Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, Heresco-Levy U, Carpenter WT.

Am J Psychiatry. 2007 Oct;164(10):1593-602.

PMID:
17898352
[PubMed - indexed for MEDLINE]
5.

Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis.

Heresco-Levy U, Javitt DC.

Schizophr Res. 2004 Feb 1;66(2-3):89-96.

PMID:
15061240
[PubMed - indexed for MEDLINE]
6.

Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site.

Shim SS, Hammonds MD, Kee BS.

Eur Arch Psychiatry Clin Neurosci. 2008 Feb;258(1):16-27. Epub 2007 Sep 27. Review.

PMID:
17901997
[PubMed - indexed for MEDLINE]
7.

D-serine added to clozapine for the treatment of schizophrenia.

Tsai GE, Yang P, Chung LC, Tsai IC, Tsai CW, Coyle JT.

Am J Psychiatry. 1999 Nov;156(11):1822-5.

PMID:
10553752
[PubMed - indexed for MEDLINE]
8.

Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis.

Tsai GE, Lin PY.

Curr Pharm Des. 2010;16(5):522-37. Review.

PMID:
19909229
[PubMed - indexed for MEDLINE]
9.

A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia.

Goff DC, Henderson DC, Evins AE, Amico E.

Biol Psychiatry. 1999 Feb 15;45(4):512-4.

PMID:
10071726
[PubMed - indexed for MEDLINE]
10.

Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients.

Javitt DC.

Curr Opin Psychiatry. 2006 Mar;19(2):151-7. Review.

PMID:
16612195
[PubMed - indexed for MEDLINE]
11.

A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia.

Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, Hayden DL, McCarley R, Coyle JT.

Arch Gen Psychiatry. 1999 Jan;56(1):21-7.

PMID:
9892252
[PubMed - indexed for MEDLINE]
12.

[Glycine therapy of schizophrenia; its rationale and a review of clinical trials].

Semba J.

Nihon Shinkei Seishin Yakurigaku Zasshi. 1998 Jun;18(3):71-80. Review. Japanese.

PMID:
9800198
[PubMed - indexed for MEDLINE]
13.

A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia.

Goff DC, Leahy L, Berman I, Posever T, Herz L, Leon AC, Johnson SA, Lynch G.

J Clin Psychopharmacol. 2001 Oct;21(5):484-7.

PMID:
11593073
[PubMed - indexed for MEDLINE]
14.

D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study.

van Berckel BN, Evenblij CN, van Loon BJ, Maas MF, van der Geld MA, Wynne HJ, van Ree JM, Kahn RS.

Neuropsychopharmacology. 1999 Aug;21(2):203-10.

PMID:
10432468
[PubMed - indexed for MEDLINE]
Free Article
15.

Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review.

Sommer IE, Begemann MJ, Temmerman A, Leucht S.

Schizophr Bull. 2012 Sep;38(5):1003-11. doi: 10.1093/schbul/sbr004. Epub 2011 Mar 21. Review.

PMID:
21422107
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.

Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE.

Arch Gen Psychiatry. 2005 Nov;62(11):1196-204.

PMID:
16275807
[PubMed - indexed for MEDLINE]
17.

Anticonvulsant effects of the glycine/NMDA receptor ligands D-cycloserine and D-serine but not R-(+)-HA-966 in amygdala-kindled rats.

Löscher W, Wlaź P, Rundfeldt C, Baran H, Hönack D.

Br J Pharmacol. 1994 May;112(1):97-106.

PMID:
8032669
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Glycine and D: -serine, but not D: -cycloserine, attenuate prepulse inhibition deficits induced by NMDA receptor antagonist MK-801.

Kanahara N, Shimizu E, Ohgake S, Fujita Y, Kohno M, Hashimoto T, Matsuzawa D, Shirayama Y, Hashimoto K, Iyo M.

Psychopharmacology (Berl). 2008 Jun;198(3):363-74. doi: 10.1007/s00213-008-1151-6. Epub 2008 Apr 24.

PMID:
18437299
[PubMed - indexed for MEDLINE]
19.

D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia.

Rosse RB, Fay-McCarthy M, Kendrick K, Davis RE, Deutsch SI.

Clin Neuropharmacol. 1996 Oct;19(5):444-50.

PMID:
8889288
[PubMed - indexed for MEDLINE]
20.

N-methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review.

Millan MJ.

Curr Drug Targets CNS Neurol Disord. 2002 Apr;1(2):191-213. Review.

PMID:
12769627
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk